JANX

SEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 4

Lichter Jay · CIK 0001376355 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,815

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 3

Lichter Jay · CIK 0001376355 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,424

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 2

Lichter Jay · CIK 0001376355 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,646

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 1

Lichter Jay · CIK 0001376355 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 9

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, LP

Disclosed balance after: 3,021,414

F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 8

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 573,227

F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 7

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,959,175

F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 6

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, LP

Disclosed balance after: 3,182,770

F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 5

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 603,840

F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 4

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,117,206

F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 3

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, L.P.

Disclosed balance after: 3,217,817

F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 2

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 610,489

F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 1

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,151,532

F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · derivative · entry 12

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,073

Underlying: Common Stock · 277 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · derivative · entry 11

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,086

Underlying: Common Stock · 414 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · derivative · entry 10

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,086

Underlying: Common Stock · 414 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · derivative · entry 9

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,006

Underlying: Common Stock · 994 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 8

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.33 to $42.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 7

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,182

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 6

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,905

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 5

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 4

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,077

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 3

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, L.P.

Disclosed balance after: 3,229,374

F3 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 2

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 612,682

F2 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 1

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,162,851

F1 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-019904 · form4-07232024_120738.xml · derivative · entry 4

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-07-18

F4 · derivative.exercise_date: The shares subject to the option will vest in twelve equal monthly installments over one year, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-019904 · form4-07232024_120738.xml · derivative · entry 3

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,700

Underlying: Common Stock · 16,700 shares

Expires 2034-07-18

F3 · derivative.exercise_date: The shares subject to the option will vest in thirty-six equal monthly installments over three years, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-019904 · form4-07232024_120738.xml · nonDerivative · entry 2

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

F2 · shares: Represents the grant of RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on July 19, 2025, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-019904 · form4-07232024_120738.xml · nonDerivative · entry 1

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in thirty-six equal monthly installments over a three year period, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-019903 · form4-07232024_120716.xml · derivative · entry 4

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-07-18

F4 · derivative.exercise_date: The shares subject to the option will vest in twelve equal monthly installments over one year, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-019903 · form4-07232024_120716.xml · derivative · entry 3

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,700

Underlying: Common Stock · 16,700 shares

Expires 2034-07-18

F3 · derivative.exercise_date: The shares subject to the option will vest in thirty-six equal monthly installments over three years, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-019903 · form4-07232024_120716.xml · nonDerivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

F2 · shares: Represents the grant of RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on July 19, 2025, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-019903 · form4-07232024_120716.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in thirty-six equal monthly installments over a three year period, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-020057 · form4a-07242024_080704.xml · derivative · entry 2

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,111

Underlying: Common Stock · 4,111 shares

Expires 2034-07-18

F2 · derivative.exercise_date: The shares subject to the option will vest in twelve equal monthly installments over one year, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-020057 · form4a-07242024_080704.xml · nonDerivative · entry 1

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,231

F1 · shares: Represents the grant of RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on July 19, 2025, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-020056 · form4a-07242024_080702.xml · derivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,111

Underlying: Common Stock · 4,111 shares

Expires 2034-07-18

F2 · derivative.exercise_date: The shares subject to the option will vest in twelve equal monthly installments over one year, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-020056 · form4a-07242024_080702.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,231

F1 · shares: Represents the grant of RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on July 19, 2025, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-018438 · form4-06282024_040635.xml · derivative · entry 2

Simson Jake · CIK 0001863094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-06-25

F3 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.

SEC source: 0001415889-24-018438 · form4-06282024_040635.xml · nonDerivative · entry 1

Simson Jake · CIK 0001863094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.

SEC source: 0001415889-24-018452 · form4-06282024_080632.xml · derivative · entry 4

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-06-25

F6 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to Dr. Simson's continuous service on each such date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Jake Simson is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option and RSU for the benefit of the Fund and the Nexus Fund II. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and RSU and underlying common stock.

SEC source: 0001415889-24-018452 · form4-06282024_080632.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,500

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to Dr. Jake Simson's continuous service on such date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Jake Simson is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option and RSU for the benefit of the Fund and the Nexus Fund II. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and RSU and underlying common stock.

SEC source: 0001415889-24-018443 · form4-06282024_040646.xml · derivative · entry 5

Lichter Jay · CIK 0001376355 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-06-25

F5 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-018443 · form4-06282024_040646.xml · nonDerivative · entry 1

Lichter Jay · CIK 0001376355 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,083

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-018441 · form4-06282024_040641.xml · derivative · entry 2

Kung Winston · CIK 0001666963 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-06-25

F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-018441 · form4-06282024_040641.xml · nonDerivative · entry 1

Kung Winston · CIK 0001666963 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-018442 · form4-06282024_040643.xml · derivative · entry 2

McNulty Alana B. · CIK 0001606086 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-06-25

F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-018442 · form4-06282024_040643.xml · nonDerivative · entry 1

McNulty Alana B. · CIK 0001606086 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-018440 · form4-06282024_040639.xml · derivative · entry 2

Gujrathi Sheila · CIK 0001575202 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-06-25

F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-018440 · form4-06282024_040639.xml · nonDerivative · entry 1

Gujrathi Sheila · CIK 0001575202 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,528

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-018439 · form4-06282024_040637.xml · derivative · entry 2

Barrett Ronald W · CIK 0001326330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-06-25

F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.